ArticlePloS one2012
Identification and characterization of antifungal compounds using a Saccharomyces cerevisiae reporter bioassay.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Shrimycocin-A, a next generation broad spectrum and systemic biofungicide from coconut shell agro waste for crop protection.Scientific reports · 2026Article
- A hundred spotlights on microbiology: how microorganisms shape our lives.Microbial cell (Graz, Austria) · 2022Article
- Unraveling the importance of molecules of natural origin in antifungal drug development through targeting ergosterol biosynthesis pathway.Iranian journal of microbiology · 2019Review
- Turning on virulence: Mechanisms that underpin the morphologic transition and pathogenicity ofVirulence · 2019Review
- Phenylpyrrole fungicides act on triosephosphate isomerase to induce methylglyoxal stress and alter hybrid histidine kinase activity.Scientific reports · 2019Article
- Yeast as a tool to identify anti-aging compounds.FEMS yeast research · 2018Review
- The antifungal pipeline: a reality check.Nature reviews. Drug discovery · 2017Review
- Stress sensitivity of a fission yeast strain lacking histidine kinases is rescued by the ectopic expression of Chk1 from Candida albicans.Current genetics · 2017Article
- Fludioxonil Induces Drk1, a Fungal Group III Hybrid Histidine Kinase, To Dephosphorylate Its Downstream Target, Ypd1.Antimicrobial agents and chemotherapy · 2017Article
- Increasing the Fungicidal Action of Amphotericin B by Inhibiting the Nitric Oxide-Dependent Tolerance Pathway.Oxidative medicine and cellular longevity · 2017Article
- A Genetic Screen for Fission Yeast Gene Deletion Mutants Exhibiting Hypersensitivity to Latrunculin A.G3 (Bethesda, Md.) · 2016Article
- Novel, Synergistic Antifungal Combinations that Target Translation Fidelity.Scientific reports · 2015Article
- A case for two-component signaling systems as antifungal drug targets.PLoS pathogens · 2015Article
- Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin.Microbial cell (Graz, Austria) · 2014Article
- Histidine phosphotransfer proteins in fungal two-component signal transduction pathways.Eukaryotic cell · 2013Review
- Cell wall perturbation sensitizes fungi to the antimalarial drug chloroquine.Antimicrobial agents and chemotherapy · 2013Article
- Antifungal drug discovery: something old and something new.PLoS pathogens · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
New antifungal drugs are urgently needed due to the currently limited selection, the emergence of drug resistance, and the toxicity of several commonly used drugs. To identify drug leads, we screened small molecules using a Saccharomyces cerevisiae reporter bioassay in which S. cerevisiae heterologously expresses Hik1, a group III hybrid histidine kinase (HHK) from Magnaporthe grisea. Group III HHKs are integral in fungal cell physiology, and highly conserved throughout this kingdom; they are absent in mammals, making them an attractive drug target. Our screen identified compounds 13 and 33, which showed robust activity against numerous fungal genera including Candida spp., Cryptococcus spp. and molds such as Aspergillus fumigatus and Rhizopus oryzae. Drug-resistant Candida albicans from patients were also highly susceptible to compounds 13 and 33. While the compounds do not act directly on HHKs, microarray analysis showed that compound 13 induced transcripts associated with oxidative stress, and compound 33, transcripts linked with heavy metal stress. Both compounds were highly active against C. albicans biofilm, in vitro and in vivo, and exerted synergy with fluconazole, which was inactive alone. Thus, we identified potent, broad-spectrum antifungal drug leads from a small molecule screen using a high-throughput, S. cerevisiae reporter bioassay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.